Finally, after nearly two decades, Exelixis (Nasdaq: EXEL) has received approval from the Food and Drug Administration for its first drug, cabozantinib. Now called Cometriq, it is used to treat advanced medullary thyroid cancer once the disease has spread to other organs. However, in this video, Motley Fool health care analyst David Williamson gives reasons to temper enthusiasm over this approval while keeping an eye on future clinical trial results for cabozantinib in prostate cancer.
You're reading a free article with opinions that may differ from The Motley Fool's Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Exelixis' Crowning Achievement
NASDAQ: EXEL
Exelixis

After 18 long years, Exelixis gets its first FDA approval.
Brenton Flynn has no positions in the stocks mentioned above. David Williamson has no positions in the stocks mentioned above. Follow him on Twitter @MotleyDavid.
The Motley Fool owns shares of AstraZeneca plc (ADR), Dendreon, and Exelixis. Motley Fool newsletter services recommend Exelixis. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Stocks Mentioned



*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.
Related Articles





Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.